The authors used a combination of computational and experimental techniques to study the variation of DNA replication fidelity among different strains of the yeast Saccharomyces cerevisiae. Their computational analysis suggested that a certain type of beer-brewing yeast accumulates mutations from C to A more quickly than other yeast, and we were able to go one step further using laboratory experiments that aren't possible in humans.
Read More
Seattle-based biotech Alpine Immune Sciences announced Wednesday it is raising roughly $91 million, before expenses, through a private placement. The biotech is expanding its pipeline and developing two of its drugs with the private placement, a means for companies to raise money by selling shares to select investors. Alpine expects the private placement to close “on or about” Friday. Frazier…
Read More
A study published today in the journal Cell Host & Microbe reported that the increased presence of certain bacteria in a gut biome indicates a greater likelihood that colon polyps will become cancerous. In his research, William DePaolo, associate professor at the University of Washington School of Medicine, tracked 40 patients who had undergone routine colonoscopies and had biopsies taken…
Read More
It wasn’t an easy hunt. No fun scavenger clues on the way. This human brain cell, still alive, was buried near the very bottom of a thin slice of the many-layered cortex, the wrinkled outermost shell of the brain. The fifth layer of the cortex, where the scientist’s target lived, is chock-full of myelin, the tough white support material that…
Read More
Silverback Therapeutics, Inc., a clinical-stage biopharmaceutical company leveraging its proprietary ImmunoTAC technology platform to develop systemically delivered, tissue targeted therapeutics for the treatment of cancer, chronic viral infections, and other serious diseases, today presented interim clinical results from a Phase 1/1b clinical study of SBT6050 as a monotherapy and in combination with pembrolizumab in patients with advanced or metastatic HER2-expressing…
Read More
Some people have a harder time losing weight than others. The current study, along with a growing body of evidence from other research groups, suggests that one of the major factors that modulate our ability to lose weight is our gut microbes. We've identified specific genetic signatures in the gut microbiome that were predictive of weight loss responses in a small cohort of patients following a healthy lifestyle intervention.
Read More

Meet the 2021-2022 ISCRM Fellows

The ISCRM Fellows program began in 2017, the year the Washington State Legislature first included funding for ISCRM in the state budget. In a critical show of support for stem cell research, the legislature appropriated $2.25 million for core staff and technologies, innovation pilot awards for faculty, and a trainee fellowship program to help the UW fulfill its mission, increase…
Read More
Links between T cell clonotypes, as defined by T cell receptor (TCR) sequences, and phenotype, as reflected in gene expression (GEX) profiles, surface protein expression and peptide:major histocompatibility complex binding, can reveal functional relationships beyond the features shared by clonally related cells. Here we present clonotype neighbor graph analysis (CoNGA), a graph theoretic approach that identifies correlations between GEX profile…
Read More

Can You Lose Weight? Ask Your Microbiome

The strongest associations with weight loss success or failure – independent of BMI – are found in the genetic capacity of the gut microbiome. These new findings open the door to diagnostic tests that can identify people likely to lose weight with healthy lifestyle changes and those who might need more drastic interventions. ISB researchers looked at 105 people who…
Read More
RareCyte, Inc., a Life Sciences company developing and manufacturing proprietary platforms enabling precision biology solutions, announced the completion of a $24M financing from new and existing investors. The funding will drive the commercialization and applications for the Company’s new Orion spatial biology platform and further global expansion for the Company’s portfolio of instruments and consumables. Arboretum Ventures led the financing…
Read More